Cerebro- and cardiovascular conditions in adults with schizophrenia treated with antipsychotic medications

Human Psychopharmacology

Volumn 22, Issue 6, 2007, Pages 361-364

  Jerrell, Jeanette M ^a   McIntyre, Roger S ^b  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adults; Antipsychotics; Cardiovascular effects; Cerebrovascular effects; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DATA ANALYSIS; DATA EXTRACTION; DISEASE ASSOCIATION; DRUG USE; DYSLIPIDEMIA; FEMALE; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAID; PATIENT IDENTIFICATION; PERIPHERAL VASCULAR DISEASE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCHIZOPHRENIA; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; COHORT STUDIES; DATABASES, FACTUAL; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SCHIZOPHRENIA;

EID: 34548251351     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.858     Document Type: Article

References (11)

1. Fontaine KR, Heo M, Harrigan EP, et al. 2001. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res 101(3): 277-288.
2. Herrmann N, Mamdani M, Lauctot KL. 2004. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 161: 1113-1115.
3. Lieberman JA, III. 2004. Metabolic changes associated with antipsychotic use. Primary Care Companion J Clin Psychiatry 6 (Suppl. 2): 8-13.
4. Marder SR, Essock SM, Miller AL, et al. 2004. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 161: 1334-1349.
5. McEvoy JP, Meyer JM, Goff DC, et al. 2005. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80: 19-32.
6. McIntyre RS, Konarski JZ. 2005. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 66 (Suppl. 3): 28-36.
7. Osby U, Brandt L, Correia N, Ekbom A, Sparen P. 2001. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 58(9): 844-850.
8. Ryan MCM, Flanagan S, Kinsella U, Keeling F, Thakore JH. 2004. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naïve patients with schizophrenia, Life Sci 74: 1999-2008.
9. Ryan MCM, Thakore JH. 2002. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci 71: 239-257.
10. Schneider LS, Dagerman KS, Insel P. 2005. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294(15): 1934-1943.
11. US Food and Drug Administration (Public Health Advisory). 2005. Deaths with antipsychotics in elderly patients with behavioral disturbances. FDA Advisory. 11-4-2005. Ref Type: Abstract http:www.fda.gov/cder/drug/ advisory/antipsychotics.htm.